Table 1

Description of methods used for evaluation of participants at baseline and at different stages of follow-up

Timing of evaluationMethods used for evaluation of participants
Sociodemographic and clinical characteristicsNeurological evaluationMoCAHADSPSQIQLQ-BR23QLQ-C30BPIDN4PDI
Main cohort of patients with breast cancer
Baseline✓*✓✓✓✓✓✓
Postsurgery✓†✓
Postchemotherapy✓‡✓
1-year follow-up✓§✓✓✓✓✓✓
3-year follow-up✓¶✓✓✓✓✓✓✓**✓**✓**
Subcohort of patients diagnosed with NP††
Baseline✓‡‡✓✓✓✓✓✓✓✓
6-month follow-up✓‡‡✓✓✓✓✓✓**✓**✓**
Subcohort of patients diagnosed with CIPN††
Baseline✓§§✓✓✓
6-month follow-up✓§§✓✓✓

  • *Data is collected on sociodemographic (birth date, address, marital status, education, occupation and alcohol consumption) and clinical (medication used, history of previous neurological disease, diabetes, hypertension, thyroid pathology and oncological history) characteristics.

  • †Data is collected on type of surgery, cancer stage51 and proposed treatment after surgery.

  • ‡Data is collected on chemotherapy (drugs used, duration of treatment and total dose).

  • §Data is collected on radiotherapy (irradiated areas, total dose and duration of treatment) and hormonotherapy (drug), and other data is updated (marital status, cancer stage51 and information regarding chemotherapy and radiotherapy).

  • ¶Data is collected on smoking habits, fruits and vegetables consumption, and physical activity. Marital status, alcohol consumption and information regarding cancer stage and treatment are reviewed.

  • **Applicable only when NP is present at the moment of evaluation.

  • ††In addition to the evaluations that are performed in the main cohort.

  • ‡‡Data is collected concerning NP symptoms, aetiology, duration, localisation and pain management.

  • §§Data is collected regarding CIPN symptoms and chemotherapy details; CIPN is graded using Common Terminology Criteria for Adverse Events V.4.052 and Total Neuropathy score.24

  • BPI, Brief Pain Inventory48 ,49; CIPN, chemotherapy-induced peripheral neuropathy; DN4, Neuropathic Pain Questionnaire47 ,48; HADS, Hospital Anxiety and Depression Scale45 ,46; MoCA, The Montreal Cognitive Assessment36 ,38; NP, neuropathic pain; PDI, Pain Disability Index48 ,50; PSQI, Pittsburgh Sleep Quality Index43 ,44; QLQ-BR23, Breast cancer-specific module of the Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer39 ,40; QLQ-C30, Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer.39 ,41